RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UC Davis UCSF
- Dates
- study startedstudy ends around
- Principal Investigator
- by Laura Huppert (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Laura Huppert (ucsf)
Dr. Laura Huppert is an oncologist who cares for patients with all stages of breast cancer. Huppert's research focuses on designing and conducting clinical trials to evaluate new cancer treatments, including ways to combine therapies so as to improve outcomes.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Hoffmann-La Roche
- Links
- Please use this form to submit your questions for a faster response: https://www.gene.com/contact-us/submit-medical-inquiry. Do not include or attach any medical records when emailing or completing the form. A nurse will respond within 24 business hours.
- ID
- NCT07413939
- Phase
- Phase 2/3 research study
- Study Type
- Interventional
- Participants
- Expecting 650 study participants
- Last Updated